Hims (HIMS): FY24 Q4 earnings call, Feb 24, 2025
No Kalshi or Polymarket word markets were listed for Hims’s Feb 24, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
25 matches for “GLP-1”; 5 quoted, at least 25 words apart.
…we'll continue to monitor and comply with regulatory requirements related to the GLP-1 shortages. And we will continue to primarily focus within our weight loss…
…high quality treatment to millions of more Americans as more brand name GLP-1 medications go generic in the coming years. As a founder-led company, we…
…new offerings such as our weight loss treatments. Revenue outside of our GLP-1 offering increased 43% year-over-year to $1.2 billion in 2024, reflecting an ability…
…run rate of over 100 million in just over seven months. Our GLP-1 offering, which launched in the second quarter of 2024, has experienced similar…
…subscriber increased 38% year-over-year to $73 in the fourth quarter. Scaling of GLP-1s as well as subscribers shifting to more premium personalized offerings are the…
Agents: this page as TSV at /api/v1/appearances/hims:2025-02-24:earnings_call · words: /api/v1/brief?appearance=hims:2025-02-24:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP